)
Pliant Therapeutics (PLRX) investor relations material
Pliant Therapeutics Registration filing summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Company overview and business model
Clinical-stage biopharmaceutical company focused on integrin-based therapeutics targeting solid tumors and other diseases.
Lead candidate, PLN-101095, is an oral dual selective inhibitor for solid tumors, with positive Phase 1 data in 2025.
Proprietary drug discovery platform with a library of over 15,000 integrin-binding molecules, enabling targeted drug delivery including siRNAs.
No approved products or product revenue; relies on external funding for ongoing operations and development.
Financial performance and metrics
No revenue from product sales to date; financials are incorporated by reference from recent SEC filings.
Audited financial statements for 2024 and 2025 are available and referenced in the filing.
Use of proceeds and capital allocation
Net proceeds from securities sales will be used for general corporate purposes, including R&D, clinical trials, working capital, capital expenditures, and potential acquisitions or investments.
Management retains broad discretion over allocation of proceeds.
- PLN-101095 advances to Phase 1b after strong Phase 1 data; net loss narrows on lower expenses.PLRX
Q4 202511 Mar 2026 - Lead oncology program shows strong early efficacy and safety, with phase Ib starting in Q2.PLRX
Oppenheimer 36th Annual Healthcare Life Sciences Conference25 Feb 2026 - Seamless phase IIb/III IPF trial advances, with strong safety and broad-label ambitions.PLRX
Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 20242 Feb 2026 - Bexotograst demonstrates robust safety and efficacy in IPF, with pivotal trial progress and market expansion plans.PLRX
2024 Wells Fargo Healthcare Conference22 Jan 2026 - Bexotegrast shows strong safety and efficacy in IPF, with pivotal trial and pipeline progress ongoing.PLRX
H.C. Wainwright 26th Annual Global Investment Conference 202421 Jan 2026 - Bexotograst shows promise in fibrotic lung diseases, with BEACON-IPF trial accelerating development.PLRX
2024 Cantor Fitzgerald Global Healthcare Conference20 Jan 2026 - Pivotal IPF program advances with strong safety, efficacy, and funding through 2027.PLRX
Immunology and Inflammation Virtual Summit20 Jan 2026 - Lead IPF therapy bexotegrast advances in pivotal trials, with strong safety and global reach.PLRX
Stifel 2024 Healthcare Conference13 Jan 2026 - BEACON-IPF study nears Q1 2025 enrollment completion, with top-line data due mid-2026.PLRX
Piper Sandler 36th Annual Healthcare Conference11 Jan 2026
Next Pliant Therapeutics earnings date
Next Pliant Therapeutics earnings date
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
Frequently asked questions
Explore our global coverage
)
)